Non-invasive Test to Detect Intra-amniotic Infection in Women With Preterm Labor and Intact Amniotic Membranes (IAI)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by ProteoGenix, Inc..
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Obstetrix Medical Group
Information provided by:
ProteoGenix, Inc.
ClinicalTrials.gov Identifier:
NCT00700219
First received: June 13, 2008
Last updated: July 19, 2010
Last verified: July 2010

June 13, 2008
July 19, 2010
June 2008
September 2010   (final data collection date for primary outcome measure)
Performance of immunoassay panel to detect intra-amniotic infection in target population. [ Time Frame: Presentation to delivery ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00700219 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Non-invasive Test to Detect Intra-amniotic Infection in Women With Preterm Labor and Intact Amniotic Membranes
Development of a Non-invasive Test to Detect Intra-amniotic Infection and Predict Preterm Birth in Women Presenting With Preterm Labor and and Intact Amniotic Membranes

The purpose of this study is to collect clinical specimens and corresponding clinical data to develop a non-invasive test for detection of intra-amniotic infection and prediction of preterm birth in women and intact amniotic membranes. The specimens collected will be used to develop a specific biomarker panel and algorithm using immunoassays for optimal detection of intra-amniotic infection in women with preterm labor and intact amniotic membranes.

Intra-amniotic infection (IAI) is an acute bacterial infection of the amniotic fluid and intrauterine contents during pregnancy and occurs in 4% to 10% of all deliveries (Newton, ER., 1993. Newton, ER, et al., 1989. Soper, DE, et al., 1989). IAI is an important cause of maternal and neonatal morbidity. Identifying and appropriately treating women with IAI is, therefore, a major obstetrical challenge.

Intrauterine infection may occur early in pregnancy and remain undetected for a prolonged period, thus exposing the fetus to the effects of infection/inflammation for a considerable period. Ideally, an early diagnosis of IAI is important to allow timely treatment and intervention. Unfortunately, the early diagnosis is difficult because the clinical signs and symptoms of IAI may occur late in the course of the infection and are neither sensitive nor specific. Therefore, to avoid a delay in diagnosis a high degree of suspicion and the appropriate use of adjunctive laboratory tests are warranted.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Cervical-vaginal Fluid, Amniotic Fluid, Maternal Serum, Neonatal Cord Blood, Maternal Urine, Placental and Umbilical Cord Tissues

Non-Probability Sample

Women presenting to labor and delivery with signs and symptoms of preterm labor and documented intact amntiotic membranes

Intra-amniotic Infection
Not Provided
1
Women presenting in preterm labor with intact amniotic membranes
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
900
September 2010
September 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is greater than or equal to 18 years of age
  • Subject has singleton gestation
  • Subject has fetus with gestational age greater than or equal to 22 0/7 weeks and less than or equal to 36 6/7 weeks
  • Subject has documented intact amniotic membranes
  • Subject's care provider plans to or has performed an amniocentesis procedure
  • Subject has had evidence of spontaneous preterm labor as evidenced by documented regular uterine contractions (greater than or equal to four per hour, or if less than 26 weeks gestation, cramping or backache) and one or more of the following:

    1. Progressive cervical change with cervical dilation of greater than or equal to 2 cm
    2. Effacement of greater than or equal to 50%
    3. Cervical length of less than or equal to 30 mm via transvaginal ultrasound
    4. Positive fetal fibronectin test

Exclusion Criteria:

  • Subject has documented ruptured amniotic membranes
  • Subject has fetus with major fetal anomaly or chromosomal aneuploidy
  • Subject has medical indication for preterm birth (e.g. pre-eclampsia)
  • Subject is unable to provide written informed consent
Female
18 Years and older
No
Contact: Desiree Hollemon, MSN, MPH 503-748-4067 hollemon@proteogenix.com
Contact: Durlin Hickok, MD 503-748-4067 hickok@proteogenix.com
United States
 
NCT00700219
PGX01-OBX0006
No
Durlin Hickok, MD, MPH, ProteoGenix, Inc.
ProteoGenix, Inc.
Obstetrix Medical Group
Principal Investigator: Andrew Combs, MD, PhD Obstetrix Medical Group of California
ProteoGenix, Inc.
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP